Which federal agency does National Association of Chain Drug Stores comment on most?

National Association of Chain Drug Stores is most active at the Food and Drug Administration.

← OpenPolis Sign in

National Association of Chain Drug Stores

Unclaimed

Industry

Nonprofit Organization Management

Staff

1776 Wilson Blvd, Arlington, Virginia

Phone

+1 703-549-3001

Website

nacds.org

Engagement overview

National Association of Chain Drug Stores has filed 174 public comments across 152 dockets at 15 federal agencies, most actively at the Food and Drug Administration.

National Association of Chain Drug Stores

Engagement overview

Is this your organization?

Agency footprint

Dockets · FDA (85)

Increasing Availability of Nonprescription Drugs; Request for Information

Developing Specifications for In-Home Disposal Systems for Opioid Analgesics Dispensed in an Outpatient Setting; Establishment of a Public Docket; Request for Comments

Amending Over-the-Counter Monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use

Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket; Request for Information and Comments

Medication Guides: Patient Medication Information; Proposed Rule

In-Home Safe Disposal Systems; Request for Information

Safety and effectiveness of certain naloxone hydrochloride drug products for nonprescription use; Request for Comments

Nonprescription Drug Product With an Additional Condition for Nonprescription Use; Proposed Rule

Revising the National Drug Code Format and Drug Label Barcode Requirements

Providing Mail-Back Envelopes and Education on Safe Disposal With Opioid Analgesics Dispensed in an Outpatient Setting; Establishment of a Public Docket; Request for Comments

Medical Devices; Ear, Nose, and Throat Devices; Establishing Over-the-Counter Hearing Aids and Aligning Other Regulations

Reconsidering Mandatory Opioid Prescriber Education Through a Risk Evaluation and Mitigation Strategy (REMS) in an Evolving Opioid Crisis; Public Workshop; Request for Comments

Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act

Enforcement Policy on National Health Related Item Code and National Drug Code Numbers Assigned to Devices

Fixed-Quantity Unit-of-Use Blister Packaging for Certain Immediate-Release Opioid Analgesics for Treatment of Acute Pain; Establishment of a Public Docket; Request for Comments

Importation of Prescription Drugs

Importation of Certain FDA-Approved Human Prescription Drugs, Including Biological Products, under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry; Availability

Instructions for Use -- Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products -- Content and Format; Draft Guidance for Industry; Availability

Nonproprietary Naming of Biological Products

Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs; Draft Guidance for Industry; Availability

Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions; Public Meeting; Request for Comments

Future Format of the National Drug Code; Public Hearing; Request for Comments

Insanitary Conditions at Compounding Facilities

Memorandum of Understanding Addressing Certain Distributions of Compounded Drug Products Between the States and the Food and Drug Administration; Revised Draft; Availability

Product Identifiers Under the Drug Supply Chain Security Act Questions and Answers; Draft Guidance for Industry

Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

Innovative Approaches for Nonprescription Drug Products; Draft Guidance for Industry; Availability

Waivers of the Single, Shared System Risk Evaluation and Mitigation Strategy Requirement

Development of a Shared System Risk Evaluation and Mitigation Strategy

Enhanced Drug Distribution Security under the Drug Supply Chain Security Act; Public Meetings; Request for Comments

Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act

Opioid Policy Steering Committee prescribing intervention – exploring a strategy for implementation; Public Hearing; Request for Comments

Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices; Immediately in Effect Guidance for Industry and Food and Drug Administration Staff; Availability

Patent Extension Application for Trulance™ U.S. Patent No. 7,041, 786

Opioid Policy Steering Committee

Review of Existing General Regulatory and Information Collection Requirements of the Food and Drug Administration

Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications

Identifying Trading Partners Under the Drug Supply Chain Security Act

Administering the Hatch-Waxman Amendments: Ensuring an Appropriate Balance Between Innovation and Access

Product Identifier Requirements Under the Drug Supply Chain Security Act-Compliance Policy

Compounding of Human Drug Products Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket

FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioids

Training for Opioid Analgesic Prescribers--Exploring the Path Forward

Proposed Pilot Project(s) under the Drug Supply Chain Security Act

Public Meeting on Progress Toward Implementing the Product Identification Requirements of the Drug Supply Chain Security Act

Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry; Availability

Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act

Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee

Toll-Free Number for Reporting Adverse Events on Labeling for Human Drug Products

Standardizing and Evaluating Risk Evaluation and Mitigation Strategies

Designation of Official Names and Proper Names for Certain Biological Products

Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application

DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs: How to Exchange Product Tracing Information; Availability

Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification

Electronic Distribution of Prescribing Information for Prescription Drug Products; Public Hearing

Draft Guidance for Industry on Drug Supply Chain Security Act Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers

Legal Status of Approved Labeling for Prescription Drugs - CLOSED

Center for Drug Evaluation and Research; Use of Innovative Packaging, Storage, and/or Disposal Systems to Address the Misuse and Abuse of Opioid Analgesics; Request for Comments

Standards for the Interoperable Exchange of Information for Tracing of Human, Finished, Prescription Drugs, in Paper or Electronic Format; Request for Comments

Pharmacy Compounding of Human Drug Products under Section 503A of the Federal Food, Drug, and Cosmetic Act

Framework for Pharmacy Compounding: State and Federal Roles

Drug Safety and Risk Management Advisory Committee; Notice of Meeting

Using Innovative Technologies and Other Conditions of Safe Use To Expand Which Drug Products Can Be Considered Nonprescription

Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009

Establishing Timeframes for Implementation of Product Safety Labeling Changes; Request for Comments

Prescription Drug User Fee Act

Periodic Review of Existing Regulations; Retrospective Review Under Executive Order 13563

Medication Guide Distribution Requirements and Inclusion of Medication Guides in Risk Evaluation and Mitigation Strategies (REMS)

Determination of System Attributes for the Tracking and Tracing of Prescription Drugs; Public Workshop

Biosimilar and Interchangeable Biological Products

Development and Distribution of Patient Medication Information for Prescription Drugs; Public Hearing

Office of the Commissioner; Request for Comments on FDA FY 2011-2015 Strategic Priorities Document

Safety Reporting Requirements Human Drug/Biological Products - CLOSED

Providing Effective Information to Consumers about Prescription Drug Risks and Benefits; Public Workshop

Joint Meeting of the Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee, and the Anesthetic and Life Support Drugs Advisory Committee; Notice of Meeting.